Replimune Group, Inc. — Director's Dealing 2021

Jan 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2021-01-13

Reporting Person: Franchi Jean M. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-13	Common Stock	M	100	$14.08	Acquired	100	Direct
2021-01-13	Common Stock	S	100	$44.19	Disposed	0	Direct
2021-01-14	Common Stock	M	14900	$14.08	Acquired	14900	Direct
2021-01-14	Common Stock	S	14300	$44.55	Disposed	600	Direct
2021-01-14	Common Stock	S	600	$44	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-13	Employee Stock Option (right to buy)	$14.08	M	100	Disposed	2029-12-09	Common Stock (100)	Direct
2021-01-14	Employee Stock Option (right to buy)	$14.08	M	14900	Disposed	2029-12-09	Common Stock (14900)	Direct

Footnotes

F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $45.00. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The reporting person continues to hold options to acquire 196,350 shares of the Issuer's common stock, 8,750 of which are exercisable as of the date hereof.

F4: 25% of the shares underlying this stock option vested on December 9, 2020, the remainder of the shares underlying this stock option will continue to vest in approximately equal monthly installments thereafter until December 9, 2023.